Midatech Pharma PLC

Receive alerts
Market Cap:
£21.49 m
52 weeks high
52 weeks low

Viewing results 1-25 of 98


Midatech appoints former GSK director to the board

Midatech said it is "very confident" Frédéric Duchesne will make an "important and positive impact" to the business ...

3 weeks, 1 day ago

Midatech Pharma hails positive results from first in man study

Researchers were assessing the safety of MTX102, which is being designed as a vaccine for type-1 diabetes...

on 19/7/19

Midatech Pharma soars following “encouraging” dose data in MTX110 study

The drug developer said the treatment has been "well tolerated" by patients in Phase I of a study designed to test its safety and efficacy...

on 3/7/19

Midatech lays out development plan for MTD201

The AIM-listed firm said it planned to develop MTD201 as a new product for the treatment of acromegaly and neuroendocrine tumours...

on 13/6/19

Midatech Pharma primed for a busy year

Here we take a closer look at Midatech Pharma PLC (LON:MTPH)...

on 15/5/19

Midatech Pharma shares jump as it looks forward to a 'value creating 18-24 months'

"We are now delivering on clinical milestones, with strong clinical data, and a compelling pipeline for our proprietary drug delivery platforms, all of which are now into the clinic"...

on 24/4/19

Midatech Pharma shares soar as it receives €6.6mln from Spanish government

The company has been conditionally granted a Reindustrialisation loan...

on 29/3/19

Midatech Pharma to change iADR ratio to try and bring price into compliance with Nasdaq minimum bid price

For ADR holders, Midatech said the change will have the same effect as a one-for-10 reverse ADR split, with the effective date of the ratio change expected to be 8 April 2019...

on 20/3/19

Midatech Pharma soars as Chinese licensing deal is approved

Shareholder approval of the investment by China Medical Systems Holdings and A&B means that a licence agreement with both is now in force...

on 26/2/19

Midatech says open offer oversubscribed, raises £13.4mln in aggregate from it, a placing and share subscription

The AIM-listed group said it received valid acceptances in respect of 20,870,414 open offer units, representing approximately 107% of the 19,456,554 units offered...

on 25/2/19

Midatech Pharma unveils plans for £4mln equity raise to support drug trials

The news comes less than a week after Midatech said Chinese billionaire, Lam Kong, would pay £8mln for a 77.3% stake in the company...

on 4/2/19

Chinese billionaire invests £8mln in AIM drug developer Midatech

Assuming shareholders approve Lam Kong’s £8mln equity investment, the billionaire’s China Medical System company will sign a licence deal that will see it develop and commercialise Midatech’s products in South East Asia...

on 29/1/19

Midatech Pharma outlines plans for drug candidate as it updates on funding position

The company provided a stark assessment of its finances ...

on 25/1/19

Midatech secures €1.5mln loan from Basque government on friendly terms

The soft loan will be used to finance the continued development of Midatech’s MTD201 drug and its related Q-Sphera drug delivery platform...

on 10/1/19

Big names in pharma starting to take note of Midatech Pharma's drug delivery technology

Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note...

on 20/12/18

Unnamed pharma giant to trial Midatech’s Q-Sphera drug delivery technology

Results from a study of Midatech’s acromegaly and carcinoid cancer drug, MTD201, earlier in the year showed that Q-Sphera works as planned...

on 20/12/18

Midatech to sell off US business as it looks to become a pure-play R&D firm

Shareholders will be asked to approve the US$19mln asset disposal, which will free up funds to develop its two key clinical programmes – MTD201 and MTX110...

on 27/9/18

Woodford will be hoping Sensyne Health can provide some remedy to his flagging funds

The star fund manager has endured a difficult time with his various funds since setting up his own firm in 2014; can Sensyne Health, which joins AIM tomorrow, provide some respite?...

on 16/8/18

Midatech making “significant progress” with two of its key clinical programmes

Early data from the first-in-human study of Midatech’s acromegaly and carcinoid cancer drug, MTD201 is due within the next few months, while its, MTX110 brain cancer treatment continues to “progress well”...

on 25/7/18

Midatech Phama signs US co-promotion deal for cancer care product

NeutraSal is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment ...

on 23/7/18

Midatech Pharma gets key clinical trial underway for cancer product

The US phase IV study will assess Gelclair's use in patients undergoing stem cell transplant therapy...

on 8/6/18

Midatech Pharma to start first-in-man trials of potential new treatment for a childhood brain cancer

Dosing has begun using Midatech’s MTX110 in patients with diffuse intrinsic pontine glioma (DIPG), a highly aggressive strain of the disease...

on 25/5/18

Midatech Pharma starts dosing of sustained release tumour treatment in equivalence study

Midatech wants to demonstrate that Q-Octreotide can achieve safe and effective growth hormone levels while also highlighting the advantages of its release system...

on 21/5/18

Midatech Pharma retreats as it pleads ignorance on share price surge; Nasdaq listing under threat

Midatech has said it will consider taking action to ensure it regains compliance with listing requirements on the Nasdaq exchange; at present, its US shares trade below the minimum bid price level of US$1...

on 3/5/18